These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interventions for hirsutism (excluding laser and photoepilation therapy alone). van Zuuren EJ; Fedorowicz Z; Carter B; Pandis N Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010334. PubMed ID: 25918921 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of antiandrogens and feminization in transgender women. Angus LM; Nolan BJ; Zajac JD; Cheung AS Clin Endocrinol (Oxf); 2021 May; 94(5):743-752. PubMed ID: 32926454 [TBL] [Abstract][Full Text] [Related]
5. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044 [TBL] [Abstract][Full Text] [Related]
6. Bioidentical hormones for women with vasomotor symptoms. Gaudard AM; Silva de Souza S; Puga ME; Marjoribanks J; da Silva EM; Torloni MR Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010407. PubMed ID: 27479272 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological interventions for those who have sexually offended or are at risk of offending. Khan O; Ferriter M; Huband N; Powney MJ; Dennis JA; Duggan C Cochrane Database Syst Rev; 2015 Feb; 2015(2):CD007989. PubMed ID: 25692326 [TBL] [Abstract][Full Text] [Related]
9. Cyproterone acetate for hirsutism. Van der Spuy ZM; le Roux PA Cochrane Database Syst Rev; 2003; 2003(4):CD001125. PubMed ID: 14583927 [TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women. Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265 [TBL] [Abstract][Full Text] [Related]
11. Variation in sensitivity and rate of change in body composition: steps toward individualizing transgender care. van Velzen DM; Nota NM; Simsek S; Conemans EB; T'Sjoen G; den Heijer M Eur J Endocrinol; 2020 Nov; 183(5):529-536. PubMed ID: 33071222 [TBL] [Abstract][Full Text] [Related]
12. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study. Muir CA; Guttman-Jones M; Man EJ Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168 [TBL] [Abstract][Full Text] [Related]
13. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents. Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Pollok J; van Agteren JE; Carson-Chahhoud KV Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235 [TBL] [Abstract][Full Text] [Related]
18. Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence. Defreyne J; Elaut E; Kreukels B; Fisher AD; Castellini G; Staphorsius A; Den Heijer M; Heylens G; T'Sjoen G J Sex Med; 2020 Apr; 17(4):812-825. PubMed ID: 32008926 [TBL] [Abstract][Full Text] [Related]